EEG Prediction and Clinical Efficacy of tDCS in Fibromyalgia.
A legfontosabb adatok
- Ki végzi
- Ionclinics & Deionic SL
- Hol
- Valencia (Spanyolország)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 250 fő, tervezett
- Kezdés
- 2026. júl. 8.
- Várható befejezés
- 2028. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- High-dose home-tDCS M1
- Conventional home-tDCS
- High-dose home-tDCS DLPFC
- A regiszteradat frissítve
- 2026. július 15.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with fibromyalgia. It compares home-based brain stimulation (tDCS) protocols and checks if a brain-wave test (EEG) predicts response.
- Életkor
- 18 Years and older
- Nem
- All sexes
- A betegség stádiuma
- Fibromyalgia by American College of Rheumatology criteria: WPI ≥7 and SSS ≥5, or WPI 4-6 and SSS ≥9. Pain in at least 4 of 5 body regions. Symptoms for at least 3 months.
- Korábbi kezelés
- Antidepressant or other medicines (or none) must be stable and kept the same during the study. No change in drug treatment in the month before the trial. No brain stimulation within the last 6 months.
A részvétel fő kizáró okai
- Immune, autoimmune, neurological or cancer diseases that explain the symptoms, such as rheumatoid arthritis or lupus
- Uncontrolled heart, kidney or liver disease
- Metal implants, head injuries, cochlear implants or pacemakers
- Personal or family history of epilepsy, or brain lesions or stroke
- Pregnancy, skin problems at electrode sites, or drug or alcohol abuse in the 3 months before
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Patients who meet the diagnostic criteria described by the American College of Rheumatology (Wolfe et al., 2016):
- Widespread Pain Index (WPI) ≥7 and Symptom Severity Scale (SSS) score ≥5 or a WPI score of 4-6 and SSS ≥9
- Presence of widespread pain, defined as pain in at least 4 of 5 regions. Jaw, chest, and abdominal pain are not included in the definition of widespread pain
- Symptoms have been generally present for at least 3 months
- The diagnosis of fibromyalgia (FM) is valid regardless of other diagnoses. The diagnosis of FM does not exclude the presence of other clinically significant diseases
- Patients with a stable prescription (or lack thereof) for antidepressant/pharmacological medication and who agree to continue it throughout the study
- Demonstrate the ability to properly administer home-based tDCS independently or with the assistance of a caregiver
- Have access to an electronic device with a camera (mobile phone or computer) to allow for monitoring of the intervention and communication with the participant
- Have the capacity and willingness to commit to the study team for the completion of all phases of the study
- Volunteer to participate and sign the specific informed consent form for this study
Ki nem vehet részt
- History of drug or alcohol abuse during the study or in the 3 months prior (except for nicotine)
- Changes in drug treatment in the month prior to starting the trial
- Presenting with immune system disorders or comorbidities that explain the main symptoms of fibromyalgia: rheumatoid arthritis, lupus, autoimmune, neurological, and oncological disorders
- Presenting with any uncompensated clinical condition such as ischemic heart disease, kidney disease, or liver disease
- Presenting with dermatological conditions, such as allergic skin reactions at the electrode sites, psoriasis, etc
- Metallic implants or head injuries, any electronic device such as cochlear implants or cardiac pacemakers
- A clinical or family history of epilepsy
- Having any structural lesion (for example, any structural neurological condition or more subcortical lesions than would be expected for their age, or having suffered a stroke affecting the stimulated area or connected areas) or any other clinically significant abnormality that could affect safety, participation in the study, or confound the interpretation of the study results, as determined by the investigator
- Any exclusion criteria established by clinical guidelines on non-invasive brain stimulation (Woods et al., 2016):
- Brain stimulation within the last 6 months
- Awaiting trial or litigation during the trial
- Pregnancy
Ez a vizsgálat jelenleg itt érhető el: Spanyolország.
- Hospital Clinico Universitario de ValenciaValencia, SpanyolországContact: IonclinicsRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its cost-effectiveness, in patients with fibromyalgia.
A teljes eredeti leírásKevesebb
As complementary goals, we aim to assess the predictive value of baseline EEG for clinical response to high-dose home-based tDCS treatment; and to describe the effectiveness of a high-dose home-based protocol applied to the motor cortex (M1) versus the dorsolateral prefrontal cortex (DLFPC) in patients with fibromyalgia.
A vizsgálat 3 csoportja
- High-dose home-tDCS M1A vizsgált kezelés
tDCS administered at home using a high-dose protocol targeting the primary motor cortex.
- Conventional home-tDCSMár használt kezelés, összehasonlításként
tDCS administered at home using a conventional stimulation protocol targeting the primary motor cortex.
- High-Dose home-tDCS DLPFCA vizsgált kezelés
tDCS administered at home using a high-dose stimulation protocol targeting the dorsolateral prefrontal cortex.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Clinical Efficacy of tDCS in Fibromyalgia: A Controlled Clinical Trial and Analysis of Electrophysiological Biomarker Predictors.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. július 15.